Proxima (formerly VantAI), a Roivant‑affiliated drug discovery firm focused on proximity‑modulating therapies, closed an $80 million seed round led by DCVC and other investors to develop AI and structural‑biology tools for designing therapeutics that control protein proximity. The company will apply its approach across cancer, immunology and other areas. Proxima said it combines proteome‑scale structural data with frontier AI models to design next‑generation proximity medicines and has existing discovery partnerships with Halda Therapeutics, Blueprint Medicines and Bristol Myers Squibb. CEO Zachary Carpenter emphasized the need for more accurate structural tools to broaden the reach of proximity modalities beyond current technical limits. The seed funding will advance platform development and pipeline initiation, according to company statements.